Pharmaceutical and Biopharmaceuticals Industries: Revolutionizing Healthcare

Rehan Haider

doi:10.55927/ajns.v2i2.4179

Authors

Rehan Haider Riggs Pharmaceuticals Department of Pharmacy The University of Karachi Pakistan

DOI:

https://doi.org/10.55927/ajns.v2i2.4179

Keywords:

Biopharmaceutical, Biosimilar, Drug Market, Monoclonal Antibodies, Recombinant Vaccines

Abstract

The pharmaceutical and biopharmaceuticals industries play a crucial role in revolutionizing healthcare by developing and delivering innovative medicines and therapies. These industries combine cutting-edge scientific research, advanced technologies, and rigorous regulatory processes to address a wide range of diseases and improve patients' lives. In this article, we will explore the key aspects of the pharmaceutical and biopharmaceuticals sectors and their impact on healthcare. Pharmaceuticals, a substance used in the diagnosis, treatment, or prevention of sickness and for restoring, correcting, or editing natural functions. A biopharmaceuticals (biological or biologic) comprising sugars, proteins, nucleic acids, living cells, or tissues is a medicinal product manufactured in extracted or semi-synthesized from natural sources like humans, animals, or microorganisms. Different from ordinary pills synthesized from chemical processes, we derive most biopharmaceuticals merchandise from natural processes alongside the extraction from residing buildings or the manufacturing with the resource of recombinant DNA used sciences. Transgenic organisms, especially plants, animals, or microorganisms that have been genetically modified, are doubtlessly used to produce biopharmaceuticals

Downloads

Download data is not yet available.

References

Chen YC, Cheng HF, Yeh MK. Cell treatment law in Taiwan. Cell Transplantation. 2017; 26 (3):483-492. DOI: 10.3727/096368916X693293.

Gonçalves GAR, Paiva RMA. Gene therapy: Advances, challenges, and perspectives. Einstein (Sao Paulo). 2017; 15 (3):369-375. DOI: 10.1590/S1679-45082017RB4024.

Marei MK, El Backley RM. Dental mesenchymal stem cell-based translational regenerative dentistry: from artificial to natural replacement. Frontiers in Bioengineering and Biotechnology. 2018; 6:49. DOI: 10.3389/fbioe.2018.00049.

Shoji T, Shinoka T. Tissue-engineered vascular grafts for pediatric cardiac surgery. Translational Pediatrics. 2018; 7 (2):188-195. DOI: 10.21037/tp.2018.02.01.

Stephenson M, Grayson W. Recent advances in bioreactors for cell-based therapies. F1000Res. 2018; 7:517. DOI: 10.12688/f1000research.12533.1. PII: F1000 Faculty Rev.

Nick C. The US Biosimilars Act: Challenges dealing with regulatory approval. Pharmaceutical Medicine. 2012; 26 (3):145-152. DOI: 10.1007/bf03262388.

Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S. Biosimilars 101: Considerations for U.S. oncologists. Cancer Medicine. 2014; 3 (4):889-899. DOI: 10.1002/cam4.258.

Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stengler T, Seidl A, Schiestl M. Maintaining the regular high-quality and scientific common overall performance of biopharmaceuticals. Expert Opinion on Biological Therapy. 2018; 18 (4):369-379. DOI: 10.1080/14712598.2018.1421169.

Strati P, Jain N, O’Brien S. Chronic lymphocytic leukemia: Diagnosis and treatment. Mayo Clinic Proceedings. 2018; 93 (5):651-664. DOI: 10.1016/j. cap.2018.03.002

Marr KA, Datta K, Mehta S, Ostrander DB, Rock M, Francis J, Feldmesser M. Urine antigen detection as a useful resource to diagnose invasive aspergillosis. Clinical Infectious Diseases. 2018. DOI: 10.1093/CID/ciy326.

Phuong NH, Kwak C, Heo CK, Cho EW, Yang J, Poo H. Development and characterization of monoclonal antibodies in opposition to nucleoprotein for prognosis of influenza A virus. Journal of Microbiology and Biotechnology, 2018; 28 (5):809-815. DOI: 10.4014/jmb.1801.01002.

Chen YC, Cheng HF, Yang YC, Yeh MK. Nanotechnologies used in biomedical vaccines. In: Stanciu SG, editor. Micro and Nanotechnologies for Biotechnology. Rijeka, Croatia: InTech; 2016. pp. 85-105. DOI: 10.5772/63453.

Chen YC, Cheng HF, Yang YC, Yeh MK. Biotechnologies used in biomedical vaccines. In: Afrin F, Hemeg H, Ozbak H, editors. Vaccine. Rijeka, Croatia: InTech; 2017. pp. 97-110. DOI: 10.5772/intechopen.69547.

Das SK, Menezes ME, Bhatia S, Wang XY, Emdad L, Sarkar D, Fisher PB. Gene redress for cancer: Strategies, challenges, and successes. Journal of Cellular Physiology. 2015; 230 (2):259-271. DOI: 10.1002/jcp.24791.

Bai Y, Gong H, Li H, Vu GP, Lu S, Liu F. Oral transport of RNase P ribozymes by Salmonella inhibits viral infections in mice. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108 (8):3222-3227. DOI: 10.1073/pnas.1014975108.

Gan WB, Grutzendler J, Wong WT, Wong RO, Lichtman JW. Multi color “idealistic” labeling of the worried computing device the use of lipophilic dye combinations. Neuron. 2000; 27 (2):219-225. DOI: 10.1016/S0896-6273 (00) 00031-3

Guo W, Guo Y, Tang S, Qu H, Zhao H. Dendritic cell-Ewing’s sarcoma mobile phone hybrids enhance antitumor immunity. Clinical Orthopaedics and Related Research. 2008; 466 (9):2176-2183. DOI: 10.1007/s11999-008-0348-7

Stewart MP, Sharei A, Ding X, Sahay G, Langer R, Jensen KF. In vitro and methods for intracellular delivery. Nature. 2016; 538 (7624):183-192. DOI: 10.1038/nature19764.

Oggi GS, Sasikumar S, Reddy N, Ella KKR, Rao CM, Bokara KK. Gene transport processes for mesenchymal stem cellular phone therapy: Strategies to prolong effectivity and specificity. Stem Cell Reviews. 2017; 13 (6):725-740. DOI: 10.1007/s12015-017-9760-2

Xiao Q, Min T, Ma S, Hu L, Chen H, Lu D. Intracellular science of single-strand template will expand the knock-in effectivity through combining CRISPR/Cas9 with AAV. Molecular Genetics and Genomics. 2018; 293 (4):1051-1060. DOI: 10.1007/s00438-018-1437-2

Finn JD, Smith AR, Patel MC, Shaw L, Younis MR, van Heteren J, Kirstine T, Ciullo C, Lescarbeau R, Seitzer J, Shah RR, Shah A, Line D, Growe J, Pink M, Rohde E, Wood KM, Salomon WE, Harrington WF, Dombrowski C, Strapps WR, Chang Y, Morrissey DV. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Reports. 2018; 22 (9):2227-2235. DOI: 10.1016/j. celrep.2018.02.014

Lau CH, Suh Y. In vivo genome editing in animals the utilization of AAV-CRISPR system: Applications to translational search for of the human disease. F1000Res. 2017; 6:2153. DOI: 10.12688/f1000research.11243.1

Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, De Luca M, Kent A, McCafé C, Munsie M, seldom-Faulkner M, Sugarman J, van Zimmern E, Zarzeczany A, Rasko JEJ. Marketing of unproven stem cell-based interventions: A identify to action. Science Translational Medicine. 2017; 9 (397):pii: eaag0426. DOI: 10.1126/scitranslmed. aag0426

Declerck P, Farouk-Rezk M, Rudd PM. Biosimilarity versus manufacturing change: Two remarkable concepts. Pharmaceutical Research. 2016; 33 (2):261-268. DOI: 10.1007/s11095-015-1790-3

Epstein MS, Ehrenpreis ED, Kulkarni PM. FDA-Related Matters Committee of the American College of Gastroenterology. Biosimilars: The need, the challenge, the future: The FDA perspective. The American Journal of Gastroenterology. 2014; 109 (12):1856-1859. DOI: 10.1038/ajg.2014.151.

Dougherty MK, Zineh I, Christl L. Perspectives on the current day kingdom of the biosimilar regulatory pathway in the United States. Clinical Pharmacology and Therapeutics. 2018; 103 (1):36-38. DOI: 10.1002/cpt.909.

Terson J, Budlong H, Affeldt T, Skiermont K, Kyllo G, Heaton A. Biosimilar merchandise in the ultra-modern U.S. health care and regulatory landscape. Journal of Managed Care & Specialty Pharmacy. 2017; 23 (12):1255-1259. DOI: 10.18553/jmcp.2017.23.12.1255endeavor.